Jefferies Group set a $40.00 target price on Pfizer (NYSE:PFE) in a research report released on Tuesday morning. The firm currently has a neutral rating on the biopharmaceutical company’s stock. Jefferies Group also issued estimates for Pfizer’s FY2017 earnings at $2.60 EPS, FY2019 earnings at $3.00 EPS, FY2020 earnings at $3.10 EPS, FY2021 earnings at $3.43 EPS and FY2022 earnings at $3.81 EPS.
Several other analysts have also recently commented on the stock. Vetr cut shares of Pfizer from a buy rating to a hold rating and set a $37.98 target price for the company. in a research note on Monday. BMO Capital Markets set a $39.00 target price on shares of Pfizer and gave the stock a buy rating in a research note on Monday, January 8th. Morgan Stanley set a $41.00 target price on shares of Pfizer and gave the stock a buy rating in a research note on Friday, January 5th. Nord/LB reissued a neutral rating on shares of Pfizer in a research note on Tuesday, January 2nd. Finally, UBS Group set a $40.00 price objective on shares of Pfizer and gave the company a buy rating in a research note on Wednesday, December 6th. Two analysts have rated the stock with a sell rating, seven have assigned a hold rating and thirteen have given a buy rating to the company’s stock. The stock presently has an average rating of Buy and an average target price of $38.94.
Pfizer (NYSE:PFE) traded up $0.58 during mid-day trading on Tuesday, reaching $37.18. 24,026,688 shares of the company’s stock traded hands, compared to its average volume of 16,976,520. The stock has a market cap of $221,620.00, a PE ratio of 22.81, a P/E/G ratio of 2.44 and a beta of 1.01. The company has a debt-to-equity ratio of 0.56, a current ratio of 1.43 and a quick ratio of 1.15. Pfizer has a 12-month low of $30.90 and a 12-month high of $37.35.
Pfizer (NYSE:PFE) last released its earnings results on Tuesday, October 31st. The biopharmaceutical company reported $0.67 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $0.65 by $0.02. The firm had revenue of $13.17 billion during the quarter, compared to analysts’ expectations of $13.17 billion. Pfizer had a net margin of 18.69% and a return on equity of 25.41%. Pfizer’s revenue for the quarter was up .9% on a year-over-year basis. During the same period in the previous year, the company earned $0.61 EPS. equities analysts anticipate that Pfizer will post 2.59 earnings per share for the current year.
Pfizer announced that its Board of Directors has authorized a share repurchase program on Monday, December 18th that allows the company to buyback $10.00 billion in shares. This buyback authorization allows the biopharmaceutical company to repurchase shares of its stock through open market purchases. Shares buyback programs are often an indication that the company’s management believes its shares are undervalued.
The firm also recently declared a quarterly dividend, which will be paid on Thursday, March 1st. Investors of record on Friday, February 2nd will be given a dividend of $0.34 per share. This represents a $1.36 dividend on an annualized basis and a yield of 3.66%. This is a boost from Pfizer’s previous quarterly dividend of $0.32. The ex-dividend date of this dividend is Thursday, February 1st. Pfizer’s dividend payout ratio is 78.53%.
In related news, insider Alexander R. Mackenzie sold 6,750 shares of the company’s stock in a transaction on Friday, December 15th. The shares were sold at an average price of $37.00, for a total transaction of $249,750.00. Following the completion of the sale, the insider now directly owns 103,458 shares of the company’s stock, valued at approximately $3,827,946. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, insider Alexander R. Mackenzie sold 14,700 shares of the business’s stock in a transaction on Wednesday, November 1st. The stock was sold at an average price of $35.30, for a total transaction of $518,910.00. Following the completion of the transaction, the insider now owns 117,432 shares in the company, valued at approximately $4,145,349.60. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 29,450 shares of company stock valued at $1,065,220. 0.06% of the stock is owned by corporate insiders.
Hedge funds have recently modified their holdings of the business. Shine Investment Advisory Services Inc. acquired a new stake in shares of Pfizer in the 2nd quarter valued at about $102,000. Mckinley Capital Management LLC Delaware acquired a new stake in shares of Pfizer in the 2nd quarter valued at about $103,000. D. Scott Neal Inc. raised its stake in shares of Pfizer by 19.3% in the 2nd quarter. D. Scott Neal Inc. now owns 3,112 shares of the biopharmaceutical company’s stock valued at $105,000 after purchasing an additional 504 shares in the last quarter. Herndon Capital Management LLC acquired a new stake in shares of Pfizer in the 2nd quarter valued at about $120,000. Finally, Americafirst Capital Management LLC acquired a new stake in shares of Pfizer in the 3rd quarter valued at about $127,000. Hedge funds and other institutional investors own 69.75% of the company’s stock.
COPYRIGHT VIOLATION NOTICE: This news story was originally published by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are accessing this news story on another domain, it was illegally stolen and republished in violation of US & international trademark & copyright legislation. The correct version of this news story can be accessed at https://www.dispatchtribunal.com/2018/01/17/pfizer-pfe-given-a-40-00-price-target-at-jefferies-group.html.
Pfizer Company Profile
Pfizer Inc (Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development and manufacture of healthcare products. Its global portfolio includes medicines and vaccines, as well as consumer healthcare products. The Company manages its commercial operations through two business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH).
Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.